MedTrace Logo

Artificial Intelligence in Predicting Progression in Multiple Sclerosis Study

NCT05426980 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 654

Last updated 2023-12-05

No results posted yet for this study

Summary

The study proposal focuses on multiple sclerosis (MS), a chronic incurable disease of the central nervous system (CNS). The MS disease is characterised by recurrent transient disability progression, quantified by increase in the extended disability status score (EDSS), and subsequent remission (disappearance of symptoms and reduced EDSS score) or, alternatively, a gradual EDSS disability progression and exacerbation of associated symptoms. At the same time, the MS is characterised by multifocal inflammatory lesions disseminated throughout the white and grey matter of the CNS, which can be observed and quantified in the magnetic resonance (MR) scans. The proposed study will address the critical unmet need of computer-assisted extraction and assessment of prognostic factors based from an individual patient's brain MR scan, such as lesion count, volume, whole-brain and regional brain atrophy, and atrophied lesion volume, in order to evaluate the capability for personalized future disability progression prediction.

Conditions

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • General and Teaching Hospital Celje

    collaborator OTHER

  • University Medical Centre Ljubljana

    collaborator OTHER

  • University Medical Centre Maribor

    collaborator OTHER

  • Izola General Hospital

    collaborator OTHER

  • University of Ljubljana

    lead OTHER

Principal Investigators

  • Ziga Spiclin, PhD · University of Ljubljana

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-13
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05426980 on ClinicalTrials.gov